Starting January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred brand status for Blue Cross and Blue Shield of Illinois, Blue Cross and Blue Shield of Montana, Blue Cross and Blue Shield of New Mexico, Blue Cross and Blue Shield of Oklahoma, and Blue Cross and Blue Shield of Texas Commercial and Exchange Affected Market formularies.